Activating mutations in BRAF, present and in up to 70% of all melanomas along with NRas mutations (present in approximately 15–20% of melanomas), result in constitutive activation of MAPK signaling, promoting growth, survival, and chemoresistance (14–17). Here, NRAS is linked to melanoma.